Latest News & Features
Europe
Biotech institute successfully challenges EPO decision revoking key CRISPR patent over priority rights | Appeal follows major changes to European law | Case returns to lower court for novelty and inventive step evaluation. 26 June 2025
Americas
Insurance company Cigna claims Bristol Myers Squibb may have caused overpayments of ‘billions’ of dollars after allegedly delaying market entry of generic Pomalyst | Lawsuit follows dismissal of antitrust suit against pharma giant over same drug. 26 June 2025
Americas
This panel brings together experts from Wolf Greenfield, BlueRock Therapeutics, BioNTech, and Generate Biomedicines to explore the evolving landscape of pharmaceutical collaborations. The discussion focuses on how partnerships can accelerate drug discovery, share risks, and pool resources in today’s complex drug development environment. 25 June 2025
Careers
Trio have worked together for several years at different firms, bringing decades of experience in medical devices, robotics, and life sciences. 24 June 2025
Europe
AstraZeneca and Kudos must disclose alternative deal structures by October 2025 | Ruling aims to clarify counterfactual damages defence ahead of expert meetings. 24 June 2025
Americas
Appeals board overturns previous decision and revokes patent on treatment worth $2bn in 2024 | Teva and Generics UK successful in arguing lack of inventive step. 24 June 2025
Americas
Coke Morgan Stewart has issued a raft of decisions under new guidance intended to improve the US patent appeals board process. But it’s a divisive issue, finds Sarah Speight. 24 June 2025
Americas
David Gindler of Orrick discusses the US Supreme Court’s ruling in Amgen v Sanofi and what it means for ongoing Section 112 litigation. The session considers how the decision has been applied—and how it may continue to be applied—by the Federal Circuit, district courts, and the PTAB, with a focus on its relevance to the life sciences sector. 23 June 2025
Europe
Court sets strict rules on rehearing's, saying "only fundamental procedural defects can be the basis for a rehearing” | Follows UK blow to Alexion, allowing biosimilars onto market. 20 June 2025
Americas
Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to Kirkland’s prior work for Regeneron | Kirkland denies conflict, citing screening measures. 19 June 2025